Study on potential markers for diagnosis of renal cell carcinoma by serum untargeted metabolomics based on UPLC-MS/MS

Objective: Renal cell carcinoma (RCC) is the most common malignancy of the kidney. However, there is no reliable biomarker with high sensitivity and specificity for diagnosis and differential diagnosis. This study aims to analyze serum metabolite profile of patients with RCC and screen for potential diagnostic biomarkers. Methods: Forty-five healthy controls (HC), 40 patients with benign kidney tumor (BKT) and 46 patients with RCC were enrolled in this study. Serum metabolites were detected by ultra-high performance liquid chromatography-tandem mass spectrometry (UPLC-MS/MS), and then subjected to multivariate statistical analysis, metabolic pathway analysis and diagnostic performance evaluation. Results: The changes of glycerophospholipid metabolism, phosphatidylinositol signaling system, glycerolipid metabolism, d-glutamine and d-glutamate metabolism, galactose metabolism, and folate biosynthesis were observed in RCC group. Two hundred and forty differential metabolites were screened between RCC and HC groups, and 64 differential metabolites were screened between RCC and BKT groups. Among them, 4 differential metabolites, including 3-β-D-Galactosyl-sn-glycerol, 7,8-Dihydroneopterin, lysophosphatidylcholine (LPC) 19:2, and γ-Aminobutyryl-lysine (an amino acid metabolite), were of high clinical value not only in the diagnosis of RCC (RCC group vs. HC group; AUC = 0.990, 0.916, 0.909, and 0.962; Sensitivity = 97.73%, 97.73%, 93.18%, and 86.36%; Specificity = 100.00%, 73.33%, 80.00%, and 95.56%), but also in the differential diagnosis of benign and malignant kidney tumors (RCC group vs. BKT group; AUC = 0.989, 0.941, 0.845 and 0.981; Sensitivity = 93.33%, 93.33%, 77.27% and 93.33%; Specificity = 100.00%, 84.21%, 78.38% and 92.11%). Conclusion: The occurrence of RCC may involve changes in multiple metabolic pathways. The 3-β-D-Galactosyl-sn-glycerol, 7,8-Dihydroneopterin, LPC 19:2 and γ-Aminobutyryl-lysine may be potential biomarkers for the diagnosis or differential diagnosis of RCC.

[1]  Xiaoquan Huang,et al.  UPLC-MS/MS-Based Serum Metabolomics Signature as Biomarkers of Esophagogastric Variceal Bleeding in Patients With Cirrhosis , 2022, Frontiers in Cell and Developmental Biology.

[2]  F. Nahm.  Receiver operating characteristic curve: overview and practical use for clinicians , 2022, Korean journal of anesthesiology.

[3]  Qian-na Zhou,et al.  Significant metabolic alterations in patients with hepatitis B virus replication observed via serum untargeted metabolomics shed new light on hepatitis B virus infection , 2021, Journal of drug targeting.

[4]  L. Matherly,et al.  Lipid metabolism reprogramming in renal cell carcinoma , 2021, Cancer and Metastasis Reviews.

[5]  Z. Fan,et al.  Untargeted GC-MS-Based Metabolomics for Early Detection of Colorectal Cancer , 2021, Frontiers in Oncology.

[6]  D. Wishart,et al.  Metabolomics in Exercise and Sports: A Systematic Review , 2021, Sports Medicine.

[7]  Gang Wu,et al.  Alterations in Faecal Metagenomics and Serum Metabolomics Indicate Management Strategies for Patients With Budd-Chiari Syndrome , 2021, Frontiers in Cellular and Infection Microbiology.

[8]  Lingling Gan,et al.  Metabolomics Profiling Discriminates Prostate Cancer From Benign Prostatic Hyperplasia Within the Prostate-Specific Antigen Gray Zone , 2021, Frontiers in Oncology.

[9]  Gang Wu,et al.  Tissue-based metabolomics reveals metabolic signatures and major metabolic pathways of gastric cancer with help of transcriptomic data from TCGA , 2021, Bioscience reports.

[10]  C. Junot,et al.  Metabolomics for personalized medicine: the input of analytical chemistry from biomarker discovery to point-of-care tests , 2021, Analytical and Bioanalytical Chemistry.

[11]  I. Hertz-Picciotto,et al.  A Comparison of Serum and Plasma Blood Collection Tubes for the Integration of Epidemiological and Metabolomics Data , 2021, Frontiers in Molecular Biosciences.

[12]  Bei Xu,et al.  Serum Metabolic Profiling Analysis of Chronic Gastritis and Gastric Cancer by Untargeted Metabolomics , 2021, Frontiers in Oncology.

[13]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[14]  N. Habermann,et al.  Untargeted Metabolomics Reveals Major Differences in the Plasma Metabolome between Colorectal Cancer and Colorectal Adenomas , 2021, Metabolites.

[15]  X. Cen,et al.  Combined transcriptomic and lipidomic analysis reveals aberrant lipid metabolism in central nervous system hemangioblastomas , 2021, Scientific Reports.

[16]  Q. Ye,et al.  High serum gamma-glutamyl transpeptidase concentration associates with poor postoperative prognosis of patients with hepatitis B virus-associated intrahepatic cholangiocarcinoma , 2020, Annals of translational medicine.

[17]  G. Suchitra,et al.  Evaluation of salivary gamma-glutamyl transpeptidase as a biomarker in oral squamous cell carcinoma and precancerous lesions , 2020, Journal of oral and maxillofacial pathology : JOMFP.

[18]  Guangji Wang,et al.  An improved detection and identification strategy for untargeted metabolomics based on UPLC-MS. , 2020, Journal of pharmaceutical and biomedical analysis.

[19]  X. Liu,et al.  Investigation of Plasma Metabolic and Lipidomic Characteristics of a Chinese Cohort and a Pilot Study of Renal Cell Carcinoma Biomarker , 2020, Frontiers in Oncology.

[20]  M. Loda,et al.  Lipids and cancer: Emerging roles in pathogenesis, diagnosis and therapeutic intervention. , 2020, Advanced drug delivery reviews.

[21]  W. Dunn,et al.  Untargeted metabolomics for uncovering biological markers of human skeletal muscle ageing , 2020, Aging.

[22]  Chun-fang Gan,et al.  Untargeted metabolomics study and pro-apoptotic properties of B-norcholesteryl benzimidazole compounds in ovarian cancer SKOV3 cells , 2020, The Journal of Steroid Biochemistry and Molecular Biology.

[23]  M. Dai,et al.  [Metabolic syndrome components and renal cell cancer risk in Chinese males: a population-based prospective study]. , 2020, Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine].

[24]  A. Fulton,et al.  Eicosanoids in Cancer: Prostaglandin E2 Receptor 4 in Cancer Therapeutics and Immunotherapy , 2020, Frontiers in Pharmacology.

[25]  B. Carr,et al.  Gamma glutamyl transpeptidase as a prognostic biomarker in hepatocellular cancer patients especially with >5 cm tumors, treated by liver transplantation , 2020, The International journal of biological markers.

[26]  H. Antti,et al.  Comprehensive metabolomics analysis of prostate cancer tissue in relation to tumor aggressiveness and TMPRSS2-ERG fusion status , 2020, BMC Cancer.

[27]  S. Gieseg,et al.  Nucleoside transporters are critical to the uptake and antioxidant activity of 7,8-dihydroneopterin in monocytic cells , 2020, Free radical research.

[28]  Qiao Wang,et al.  Integrated strategy for accurately screening biomarkers based on metabolomics coupled with network pharmacology. , 2020, Talanta.

[29]  J. Prados,et al.  Discovery of Pancreatic Adenocarcinoma Biomarkers by Untargeted Metabolomics , 2020, Cancers.

[30]  X. Liu,et al.  A pilot investigation of a urinary metabolic biomarker discovery in renal cell carcinoma , 2019, International Urology and Nephrology.

[31]  Yue Hu,et al.  Application of metabolomics by UHPLC-MS/MS in diagnostics and biomarker discovery of non-small cell lung cancer , 2019, Translational cancer research.

[32]  X. Liu,et al.  Urine Metabolomics for Renal Cell Carcinoma (RCC) Prediction: Tryptophan Metabolism as an Important Pathway in RCC , 2019, Front. Oncol..

[33]  R. Forsgård.  Lactose digestion in humans: intestinal lactase appears to be constitutive whereas the colonic microbiome is adaptable , 2019, The American journal of clinical nutrition.

[34]  Rima Kaddurah-Daouk,et al.  Untargeted Metabolomic Profiling Identifies Disease-specific Signatures in Food Allergy and Asthma. , 2019, The Journal of allergy and clinical immunology.

[35]  R. Gray,et al.  Renal Cell Carcinoma: Diagnosis and Management. , 2019, American family physician.

[36]  F. Bray,et al.  Epidemiology of Renal Cell Carcinoma. , 2019, European urology.

[37]  Z. Cai,et al.  statTarget: A streamlined tool for signal drift correction and interpretations of quantitative mass spectrometry-based omics data. , 2018, Analytica chimica acta.

[38]  Haldun Akoglu,et al.  User's guide to correlation coefficients , 2018, Turkish journal of emergency medicine.

[39]  Hongwei Li,et al.  Serum Lipidomics Profiling to Identify Biomarkers for Non-Small Cell Lung Cancer , 2018, BioMed research international.

[40]  Christa Boer,et al.  Correlation Coefficients: Appropriate Use and Interpretation , 2018, Anesthesia and analgesia.

[41]  E. Lam,et al.  Renal cell carcinoma: a review of biology and pathophysiology , 2018, F1000Research.

[42]  Yong Dong,et al.  Tumor and serum gamma-glutamyl transpeptidase, new prognostic and molecular interpretation of an old biomarker in gastric cancer , 2017, Oncotarget.

[43]  Mark R Viant,et al.  How close are we to complete annotation of metabolomes? , 2017, Current opinion in chemical biology.

[44]  P. Sacchetta,et al.  Advances in Lipidomics for Cancer Biomarkers Discovery , 2016, International journal of molecular sciences.

[45]  Chi V. Dang,et al.  From Krebs to clinic: glutamine metabolism to cancer therapy , 2016, Nature Reviews Cancer.

[46]  N. Petejová,et al.  Renal cell carcinoma: Review of etiology, pathophysiology and risk factors. , 2016, Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia.

[47]  R. Zare,et al.  MYC oncogene overexpression drives renal cell carcinoma in a mouse model through glutamine metabolism , 2015, Proceedings of the National Academy of Sciences.

[48]  A. Czarnecka,et al.  The role of prostaglandin E2 in renal cell cancer development: future implications for prognosis and therapy. , 2014, Future oncology.

[49]  R. Rajandram,et al.  Evaluation of steroid hormones and their receptors in development and progression of renal cell carcinoma , 2014, Journal of kidney cancer and VHL.

[50]  R. Weiss,et al.  Kidney tumor biomarkers revealed by simultaneous multiple matrix metabolomics analysis. , 2012, Cancer research.

[51]  Florian Kronenberg,et al.  Differences between Human Plasma and Serum Metabolite Profiles , 2011, PloS one.